VX-765 is primarily investigated for its potential therapeutic applications in inflammatory and autoimmune diseases. It functions as a selective inhibitor of caspase-1, an enzyme involved in the production of pro-inflammatory cytokines such as IL-1β and IL-18. By inhibiting caspase-1, VX-765 can reduce inflammation and tissue damage associated with conditions like rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Preclinical studies suggest its efficacy in modulating inflammatory responses, making it a promising candidate for treating chronic inflammatory disorders. Additionally, research is exploring its potential in neuroinflammatory conditions, such as Alzheimer's disease and multiple sclerosis, where excessive inflammation contributes to disease progression. However, further clinical trials are necessary to confirm its safety and efficacy in humans.